- Pacific Biosciences of California ( NASDAQ: PACB ) said it expects to offer and sell $150M shares in an underwritten public offering.
- PacBio also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5M shares at the public offering price, less underwriting discounts and commissions.
- PacBio will use the net proceeds from the offering for research and development, and may also use a portion to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property.
For further details see:
Pacific Bio announces public offering of $150M shares